Innovation & Research

We are heavily committed to healthcare delivery in the countries and communities in which we operate and because we continually liaise with important stakeholders. These include Academia, Pharmacists, Doctors, Nurses, Hospitals, Clinics, Pharmaceutical Associations, Community Leaders, National health Organisations and Patients.

Millions of people, especially in developing countries are needlessly dying from both infectious and avoidable diseases or falling ill due to continued lack of access to basic medical care, essential medicines and vaccines. This is our main area of focus.

Our innovative work with partners who share our cardinal objective of providing and enhancing access to vital disease-fighting drugs and vaccines are committed to assisting developing countries, especially West Africa where our services are mostly needed to improve well-being.

Pharmaceuticals News

Aug 28, 2014 European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)

European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myas

More News
For General
Enquiries Call Us on + 44 (0) 1189 653845